Aegerion Pharmaceuticals has a conference call on July 30, 2013, to review the 2nd Quarter financial results and recent progress with the launch of orphan drug Juxtapid (Lomitapide). Juxtapid is FDA approved for the treatment of the ultra-rare disease Homozygous Familial Hypercholesterolemia (HoFH). Investors are watching closely to see what the status and finances are for Juxtapid. The drug receives FDA approval in December 2012 with a launch in January 2013 in the US.
Read more: http://bit.ly/1bQplEZ